CompletedPhase 3NCT00060398
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Studying Myelodysplastic neoplasm with low blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- Shirley S. Hwang, RN, MSVeterans Affairs Medical Center - East Orange
- Intervention
- epoetin alfa(biological)
- Enrollment
- 282 target
- Eligibility
- 18-120 years · MALE
- Timeline
- 2004
Study locations (30)
- Memorial Medical Center Cancer Services, Modesto, California, United States
- Aurora Presbyterian Hospital, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States
- St. Joseph Hospital, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- CCOP - Colorado Cancer Research Program, Incorporated, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- Sky Ridge Medical Center, Lone Tree, Colorado, United States
- Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
- St. Mary-Corwin Regional Medical Center, Pueblo, Colorado, United States
- North Suburban Medical Center, Thornton, Colorado, United States
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00060398 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with low blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07328191Quality of Life-Guided Transfusion in Refractory MDS or AMLCentre Hospitalier Universitaire de Nice
- RECRUITINGPHASE2NCT06918834Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome PatientsInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07019155Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition VariantsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT06144515Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic SyndromeMinovia Therapeutics Ltd.
- RECRUITINGPHASE2NCT05924100Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDAssociazione Qol-one
- RECRUITINGPHASE1NCT05473910A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem TransplantationTScan Therapeutics, Inc.
- RECRUITINGNCT02269592Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeDana-Farber Cancer Institute
See all trials for Myelodysplastic neoplasm with low blasts →